Increased high-grade prostate cancer and finasteride—sampling density bias?
This article has no abstract so we have provided the first paragraph of the full text.
The Prostate Cancer Prevention Trial (PCPT) of finasteride for prostate cancer prevention resulted in a 24.8% reduction in the 7-year period prevalence of prostate cancer for patients taking finasteride versus placebo. However, the study also found a higher incidence of high-grade (Gleason score 7–10) tumors in biopsy samples from the finasteride group, raising fears that finasteride might selectively promote high-grade tumors.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.